CAS: 1417576-00-1; (5-Methyl-2-Oxo-1,3-Dioxol-4-yl)Methyl 2-Oxo-3-((2'-(5-Oxo-4,5-Dihydro-1,2,4-Oxadiazol-3-yl)-[1,1'-Biphenyl]-4-yl)Methyl)-2,3-Dihydro-1H-Benzo[d]Imidazole-4-Carboxylate

该化合物是Azilsartan Medoxomil的一种活性代谢物,一种有选择性的血管受体阻塞器(ARB),用于抗血压抑制疗法,作为一种药性活性衍生物,它对AT1受体表现出高度的亲近性,有效抑制乙酰腺素乙型血管诱发的血管凝聚,其主要优势包括代谢稳定性提高,生物利用率比其原药型强.该化合物显示出强效和持续的减压性血压效应,具有有利的药用植物动力学特征,其选择性行动最大限度地减少非目标效果,使其成为心血管治疗药物研发的宝贵中间体.代乙基甲状腺素甲状腺素甲状腺素的分析标准对于药物制造的代谢研究和质量控制至关重要.

英文名称(5-Methyl-2-Oxo-1,3-Dioxol-4-yl)Methyl 2-Oxo-3-((2'-(5-Oxo-4,5-Dihydro-1,2,4-Oxadiazol-3-yl)-[1,1'-Biphenyl]-4-yl)Methyl)-2,3-Dihydro-1H-Benzo[d]Imidazole-4-Carboxylate
中文名称美阿沙坦钾杂质B
IUPAC名称(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-oxo-3-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate
其它别名Azilsartan Impurity 16; 2-Oxo-3-[2'-(5-Oxo-4,5-Dihydro-[1,2,4]Oxadiazol-3-yl)-Biphenyl-4-Yl Methyl]-3H-Benzoimidazole-4-Carboxylic Acid 5-Methyl-2-Oxo-{1,3}Dioxol-4-Ylmethyl Ester; Azilsartan Medoxomil O-Desethyl; 1H-Benzimidazole-4-Carboxylic Acid, 3-[[2'-(2,5-Dihydro-5-Oxo-1,2,4-Oxadiazol-3-yl)[1,1'-Biphenyl]-4-Yl]Methyl]-2,3-Dihydro-2-Oxo-, (5-Methyl-2-Oxo-1,3-Dioxol-4-yl)Methyl Ester; (5-Methyl-2-Oxo-1,3-Dioxol-4-yl)Methyl 2-Oxo-3-((2'-(5-Oxo-4,5-Dihydro-1,2,4-Oxadiazol-3-yl)-[1,1'-Biphenyl]-4-yl)Methyl)-2,3-Dihydro-1H-Benzo[d]Imidazole-4-Carboxylate; Azilsartan Impb
CAS编号1417576-00-1
MFCD编号:MFCD35147365
FDA UNII编号:TT4XUK68VA
分子式:C28H20N4O8分子量:540.49
产品CID: 639506
产品分类分析化学 → 标准品 → 药典标准品和杂质标准品

相似结构搜索
InChIKey: MZPRTKPTVHPGEW-UHFFFAOYSA-N
InChI=1S/C28H20N4O8/c1-15-22(39-28(36)38-15)14-37-25(33)20-7-4-8-21-23(20)32(26(34)29-21)13-16-9-11-17(12-10-16)18-5-2-3-6-19(18)24-30-27(35)40-31-24/h2-12H,13-14H2,1H3,(
计算化学: 氢键受体数9.0氢键供体数2.0可旋转键数8.0

物理性质

密度1.54±0.1 g/cm3(预测)
pKa:6.85±0.20(预测)
溶解性DMSO (Slightly), Methanol (Slightly, Heated)
外观形态白色至类白色固体
储存条件 Inert atmosphere, 2-8°C
产品应用该化合物用于降低高血压.当AZILSARTAN MEDOXOMIL进入胃肠道时,它会迅速转化为活性形式AZILSTAN(A 926900).

MSDS等安全信息

警示词Warning
危险描述H361-H413-
防范说明P201-P202-P273-P280-P308+P313-P405-P501-

上下游产品

ethyl 1-[(2'-cyano-[1,1']-biphenyl-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate methyl 2-ethoxy-1-((2′-(N′-hydroxycarbamimidoyl)-biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate ethyl 2-ethoxy-1-((2′-(N′-hydroxycarbamimidoyl)biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate methyl 2-ethoxy-1-((2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1H-benzo[d]-imidazole-7-carboxylate

合成工艺路线路线简述

📜阿齐沙坦置于盐酸,4-二甲氨基吡啶,Potassium Carbonate,对甲苯磺酰氯体系中,用 N,N-二甲基乙酰胺,水,丙酮用作溶剂,化学反应 4.0H,反应生成美阿沙坦钾杂质b
参考文献:Improved Process For Azilsartan Medoxomil: A New Angiotensin Receptor Blocker
标题:Improved Process For Azilsartan Medoxomil: A New Angiotensin Receptor Blocker
摘要:An Improved Process For The Active Pharmaceutical Ingredient Of A New Angiotensin Ii At(1) Receptor Antagonist,Azilsartan Medoxomil,Has Been Developed. The Results Include Reinvestigation Of The Described Process As Well As Its Novel Modifications. This New Process Includes Transformation Of The Cn Group Into Amidoxime Moiety By Aqueous Hydroxylamine,Its Cyclization Into The Corresponding Oxadiazole By Treatment With Dialkyl Carbonates,And The Following Hydrolysis Of The Ester And Transformation Into The Medoxomil Ester. Several Thus Far Undocumented Side Products Were Identified,And Some Of Them Were Synthesized And Duly Characterized As Potential Impurities. Formation And Control Of Possible Critical Impurities Are Described.
Doi:10.1021/op3002867